Table 2.
Ongoing clinical trials examining cardiovascular effects of angiotensin-(1–7) pathway activation
| Institution | Study Title | Population | Route, Drug | Endpoints | NCT number |
|---|---|---|---|---|---|
| Penn State | Cardiovascular Effects of Angiotensin-(1–7) in Obesity | Obesity Hypertension | Intravenous, Ang-(1–7) | Brachial and coronary blood flow, BP, HR, MSNA | NCT03604289 |
| Penn State | Protective effects of Angiotensin-(1–7) in PAD | Peripheral Arterial Disease | Intravenous, Ang-(1–7) | Leg blood flow, inflammatory markers, BP, HR | NCT03240068 |
| Vanderbilt | BP lowering effects of Angiotensin-(1–7) in primary autonomic failure | Primary Autonomic Failure | Intravenous, Ang-(1–7) | BP, HR | NCT02591173 |
| Vanderbilt | Cardiovascular effects of Angiotensin-(1–7) in essential hypertension | Essential hypertension | Intravenous, Ang-(1–7) | BP | NCT02245230 |
| Penn State | Angiotensin-(1–7) and Energy Expenditure in Human Obesity | Obesity | Intravenous, Ang-(1–7) | Energy expenditure, BP, HR | NCT03777215 |
| Vanderbilt | Metabolic Effects of Angiotensin-(1–7) | Obesity | Intravenous, Ang-(1–7) | Insulin sensitivity, BP, HR, cardiac output, stroke volume, vascular resistance | NCT02646475 |
| Instituto de Cardiologia do Rio Grande do Sul | Acute Effect of Angiotensin-(1–7) in Healthy and Hypertensive Subjects | Healthy and Essential Hypertension |
Intravenous, Ang-(1–7) | Adverse effects, BP, BP variability, HR, HR variability | NCT3001271 |
| University Hospital Basel | Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2) | Healthy | Intravenous, rhACE2 | Adverse events, vital signs (BP, RR, HR), blood chemistry, ECG parameters | NCT00886353 |
| GlaxoSmithKline | A Dose-escalation Study in Subjects with Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Intravenous, rhACE2 | Pulmonary vascular resistance, cardiac output, mean pulmonary artery pressure, adverse events | NCT03177603 |
| Vanderbilt | Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Intravenous, rhACE2 | Sex hormone metabolites, insulin resistance, oxidative stress, triglycerides | NCT01884051 |
| GlaxoSmithKline | The Safety, Tolerability, PK and PD of GSK2586881 in Patients with Acute Lung Injury | Acute Lung Injury and ARDS | Intravenous, rhACE2 | BP, HR, ECG parameters, hematology parameters, blood chemistry | NCT01597635 |
Abbreviations: Ang, angiotensin; ARDS, acute respiratory distress syndrome; BP, blood pressure; ECG, electrocardiogram; GSK2586881, recombinant human ACE2; HR, heart rate; MSNA, muscle sympathetic nerve activity; NCT, https://clinicaltrials.gov registry number; rhACE2, recombinant human ACE2.